Recent Developments in Bisphosphonate Therapy

Seminars in Arthritis and Rheumatism

Volumn 37, Issue 1, 2007, Pages 1-12

  Silverman, Stuart L ^a   Maricic, Michael ^b  

^a Osteoporosis Medical Center   (United States)

^b Catalina Pointe Clinical Research Inc   (United States)

Author keywords

bisphosphonates; glucocorticoid induced osteoporosis; postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ETIDRONIC ACID; GLUCOCORTICOID; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; PREDNISOLONE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ANEMIA; ANKYLOSING SPONDYLITIS; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE METASTASIS; BONE MINERALIZATION; BONE NECROSIS; BONE PAIN; BRONCHITIS; CEREBRAL PALSY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; EPIGASTRIC PAIN; ESOPHAGITIS; FEVER; FIBROUS DYSPLASIA; FLU LIKE SYNDROME; FRACTURE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HIP FRACTURE; HUMAN; HYPERCALCEMIA; HYPERTENSION; INJECTION SITE REACTION; JAW OSTEONECROSIS; JUVENILE OSTEOPOROSIS; LEG PAIN; META ANALYSIS; MORBIDITY; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEPHROTOXICITY; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PAGET BONE DISEASE; PATHOGENESIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RETICULOHISTIOCYTOSIS; RHEUMATOID ARTHRITIS; RISK REDUCTION; SINGLE DRUG DOSE; SPONDYLOARTHROPATHY; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VERTEBRA FRACTURE;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 34447651173     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2006.12.003     Document Type: Article

References (101)

1. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21 (2000) 115-137
2. Epstein S., and Zaidi M. Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone 37 (2005) 433-440
3. Muhlbauer R.C., Bauss F., Schenk R., Janner M., Bosies E., Strein K., et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6 (1991) 1003-1011
4. Carano A., Teitelbaum S.L., Konsek J.D., Schlesinger P.H., and Blair H.C. BP directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 85 (1990) 456-461
5. Adachi K., and Chole R.A. Inhibition of osteoclast recruitment at a local site by 1-hydroxyethylidene-1,1-bisphosphonate (HEBP). Ann Otol Rhinol Laryngol 99 (1990) 738-741
6. Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10 (1995) 1478-1487
7. Coxon F.P., Thompson K., and Rogers M.J. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 6 (2006) 307-312
8. van Beek E., Pieterman E., Cohen L., Lowik C., and Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264 (1999) 108-111
9. Rodan G.A., and Fleisch H.A. Bisphosphonates: mechanisms of action. J Clin Invest 97 (1996) 2692-2696
10. Delmas P.D., Recker R.R., Chesnut III C.H., Skag A., Stakkestad J.A., Emkey R., et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15 (2004) 792-798
11. Consensus Development Conference: prophylaxis and treatment of osteoporosis. Am J Med 1 (1991) 107-110
12. Forsblad d'Elia H., Larsen A., Waltbrand E., Kvist G., Mellstrom D., Saxne T., et al. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Ann Rheum Dis 62 (2003) 617-623
13. Manolagas S., and Weinstein R. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 14 (1999) 1061-1066
14. Bone Health and Osteoporosis: A Report of the Surgeon General (2004), U.S. Department of Health and Human Services, Office of the Surgeon General, Rockville, MD
15. Zizic T.M. Pharmacologic prevention of osteoporotic fractures. Am Fam Physician 70 (2004) 1293-1300
16. Riggs B.L., and Melton III L.J. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17 (1995) 505S-511S
17. Nevitt M.C., Ettinger B., Black D.M., Stone K., Jamal S.A., Ensrud K., et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128 (1998) 793-800
18. Ensrud K.E., Thompson D.E., Cauley J.A., Nevitt M.C., Kado D.M., Hochberg M.C., et al., Fracture Intervention Trial Research Group. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. J Am Geriatr Soc 48 (2000) 241-249
19. Cauley J.A., Thompson D.E., Ensrud K.C., Scott J.C., and Black D. Risk of mortality following clinical fractures. Osteoporos Int 11 (2000) 556-561
20. Kado D.M., Browner W.S., Palermo L., Nevitt M.C., Genant H.K., and Cummings S.R. Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 159 (1999) 1215-1220
21. Kotowicz M.A., Melton III L.J., Cooper C., Atkinson E.J., O'Fallon W.M., and Riggs B.L. Risk of hip fracture in women with vertebral fracture. J Bone Miner Res 9 (1994) 599-605
22. Wasnich R.D., and Miller P.D. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85 (2000) 231-236
23. Empana J.P., Dargent-Molina P., and Breart G. Effect of hip fracture on mortality in elderly women: the EPIDOS prospective study. J Am Geriatr Soc 52 (2004) 685-690
24. Rosen C., Hochberg M., Bonnick S., McClung M., Miller P., Broy S., et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20 (2005) 141-151
25. Miller P.D., McClung M.R., Macovei L., Stakkestad J.A., Luckey M., Bonvoisin B., et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20 (2005) 1315-1322
26. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11 (2000) 83-91
27. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282 (1999) 1344-1352
28. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344 (2001) 333-340
29. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al., Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348 (1996) 1535-1541
30. Chesnut C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19 (2004) 1241-1249
31. Hodsman A.B., Hanley D.A., and Josse R. Do bisphosphonates reduce the risk of osteoporotic fractures?. An evaluation of the evidence to date. CMAJ 166 (2002) 1426-1430
32. Boonen S., Laan R.F., Barton I.P., and Watts N.B. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 16 (2005) 1291-1298
33. Marcus R., Wong M., Heath III H., and Stock J.L. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 23 (2002) 16-37
34. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
35. Cranney A., Wells G., Willan A., Griffith L., Zytaruk N., Robinson V., et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23 (2002) 508-516
36. Delmas P.D., Adami S., Strugala C., Stakkestad J.A., Reginster J.Y., Felsenberg D., et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54 (2006) 1838-1846
37. Coleman R.E. Bisphosphonates: clinical experience. Oncologist 9 Suppl 4 (2004) 14-27
38. Reid I.R., Brown J.P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346 (2002) 653-661
39. Black D.M.B.S., Cauley J., Delmas P., Eastell R., Reid I., Rosario-Jansen T., et al. Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: The HORIZON Pivotal Fracture Trial. J Bone Miner Res 21 (2006) S16
40. Black D.M.B.S., Cauley J., Delmas P., et al. Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: The HORIZON Pivotal Fracture Trial (2006) Paper presented at ASBMR 28th Annual Meeting; September 15-19, 2006, Philadelphia, PA, Abstract 1054;
41. Recker R.R., Boonen S., Garcia P., Supronik J., Peichl P., Black D., et al. The effect of annual treatment with zoledronic acid 5 mg on bone remodeling: bone histomorphometry results from the HORIZON-PFT. J Bone Miner Res 21 (2006) S290
42. Delmas P.D. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol 17 (2005) 462-466
43. Ott S.M. Ten years of alendronate treatment for osteoporosis in postmenopausal women. N Engl J Med 351 (2004) 190-192 author reply 190-2.
44. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 (2004) 1189-1199
45. Ensrud K.E., Barrett-Connor E.L., Schwartz A., Santora A.C., Bauer D.C., Suryawanshi S., et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 19 (2004) 1259-1269
46. Sambrook P.N., Rodriguez J.P., Wasnich R.D., Luckey M.M., Kaur A., Meng L., et al. Alendronate in the prevention of osteoporosis: 7-year follow-up. Osteoporos Int 15 (2004) 483-488
47. Black D.S.A., Ensrud K., Rybak-Feiglin A., Gupta J., Lombardi A., Wallace R.L.S., et al. A 5 year randomized trial of the long-term efficacy and safety of alendronate. J Bone Mineral Res 10 (2004) S45
48. Ensrud K.D.S., Kimmel D., Recker R.R., Masarachia P., Lombardi A., and Wehren L. Bone histomorphometry following 10 years alendronate treatment. [abstract]. Osteoporos Int (2005) The Sixth International Symposium on Osteoporosis: Current Status and Future Directions, Washington, DC.
49. Mellstrom D.D., Sorensen O.H., Goemaere S., Roux C., Johnson T.D., and Chines A.A. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75 (2004) 462-468
50. Kendler D.W.N.B., Zhou X., Harris S.T., and Grauer A. Magnitude of change in BMD and bone turnover markers after cessation of risedronate treatment; biological effect or statistical phenomenon?. J Bone Miner Res 20 (2005) S402
51. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., and Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100 (1997) 1475-1480
52. American College of Rheumatology, and American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44 (2001) 1496-1503
53. Yeap S.S., and Hosking D.J. Management of corticosteroid-induced osteoporosis. Rheumatology 41 (2002) 1088-1094
54. van Staa T.P., Leufkens H.G.M., Abenhaim L., Zhang B., and Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology 39 (2000) 1383-1389
55. Gudbjornsson B., Juliusson U.I., and Gudjonsson F.V. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 61 (2002) 32-36
56. Saag K.G., Emkey R., Schnitzer T.J., Brown J.P., Hawkins F., Goemaere S., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339 (1998) 292-299
57. Adachi J.D., Bensen W.G., Brown J., Hanley D., Hodsman A., Josse R., et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337 (1997) 382-388
58. Ringe J., Dorst A., Faber H., Ibach K., and Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 14 (2003) 801-807
59. Reid I.R., Miller P., Lyles K., Fraser W., Brown J.P., Saidi Y., et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 353 (2005) 898-908
60. Maricic M. The use of zoledronic acid for Paget's disease of bone. Curr Osteoporos Rep 4 (2006) 40-44
61. Selby P.L. Pamidronate in the treatment of Paget's disease. Bone 24 (1999) 57S-58S
62. Siris E.S. Paget's disease of bone. J Bone Miner Res 13 (1998) 1061-1065
63. Thiebaud D., Jaeger P., Gobelet C., Jacquet A.F., and Burckhardt P. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone. Am J Med 85 (1988) 207-212
64. Walsh J.P., Ward L.C., Stewart G.O., Will R.K., Criddle R.A., Prince R.L., et al. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Bone 34 (2004) 747-754
65. Dougados M., Dijkmans B., Khan M., Maksymowych W., van der Linden S., and Brandt J. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 61 (2002) 40iii-50
66. Maksymowych W.P., Jhangri G.S., Fitzgerald A.A., LeClercq S., Chiu P., Yan A., et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 46 (2002) 766-773
67. Toussirot E., and Wendling D. Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies. Expert Opin Pharmacother 6 (2005) 35-43
68. Ward L.M., Denker A.E., Porras A., Shugarts S., Kline W., Travers R., et al. Single-dose pharmacokinetics and tolerability of alendronate 35 and 70 mg tablets in children and adolescents with osteogenesis imperfecta type I. J Clin Endocrinol Metab 90 7 (2005) 4051-4056
69. Speiser P.W., Clarson C.L., Eugster E.A., Kemp S.F., Radovick S., Rogol A.D., et al. Bisphosphonate treatment of pediatric bone disease. Pediatr Endocrinol Rev 3 (2005) 87-96
70. Trotta F., Castellino G., and Lo Monaco A. Multicentric reticulohistiocytosis. Best Pract Res Clin Rheumatol 18 (2004) 759-772
71. Goto H., Inaba M., Kobayashi K., Imanishi Y., Kumeda Y., Inui K., et al. Successful treatment of multicentric reticulohistiocytosis with alendronate: evidence for a direct effect of bisphosphonate on histiocytes. Arthritis Rheum 48 (2003) 3538-3541
72. Fosamax (alendronate sodium) US Prescribing Information. Available at: http://www.fosamax.com/alendronate_sodium/fosamax/consumer/product_information/pi/index.jsp?WT.svl=1. Accessed July 24, 2006.
73. Boniva tablets (ibandronate sodium) US Prescribing Information. Available at: http://boniva.com/prescribing_info.aspx0. Accessed July 24, 2006.
74. Boniva injection (ibandronate sodium) US Prescribing Information. Available at http://www.rocheusa.com/products/Boniva/Injection_PI.pdf. Accessed September 20, 2006.
75. Aredia (pamidronate) US Prescribing Information. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/aredia.pdf. Accessed September 20, 2006.
76. Actonel (risedronate sodium tablets) US Prescribing Information. Available at: http://www.actonel.com/global/prescribing_information_aug.pdf. Accessed November 5, 2006.
77. Zometa (zoledronic acid) US Prescribing Information. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/Zometa.pdf. Accessed September 20, 2006.
78. Bauer D.C., Black D., Ensrud K., Thompson D., Hochberg M., Nevitt M., et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 160 (2000) 517-525
79. Taggart H., Bolognese M., Lindsay R., Ettinger M., Mulder H., Josse R., et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 77 (2002) 262-270
80. Ettinger M.P., Felsenberg D., Harris S.T., Wasnich R., Skag A., Hiltbrunner V., et al. Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. J Rheumatol 32 (2005) 1968-1974
81. de Groen P.C., Lubbe D.F., Hirsch L.J., Daifotis A., Stephenson W., Freedholm D., et al. Esophagitis associated with the use of alendronate. N Engl J Med 335 (1996) 1016-1021
82. Adami S., Felsenberg D., Christiansen C., Robinson J., Lorenc R.S., Mahoney P., et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 34 (2004) 881-889
83. Miller R.G., Chretien K.C., Meoni L.A., Liu Y.P., Klag M.J., and Levine M.A. Comparison of intravenous pamidronate to standard therapy for osteoporosis: use in patients unable to take oral bisphosphonates. J Clin Rheumatol 11 (2005) 2-7
84. Chang J.T., Green L., Beitz J., Tarassoff P., Hei Y.-J., and Maladorno D. Renal failure with the use of zoledronic acid. N Engl J Med 349 (2003) 1676-1679
85. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 (2002) 1458-1468
86. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98 (2003) 1735-1744
87. Stakkestad J.A., Benevolenskaya L.I., Stepan J.J., Skag A., Nordby A., Oefjord E., et al. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 62 (2003) 969-975
88. Zaidi M., Lewiecki E.M., Bolognese M.A., and Friend K.E. Safety and tolerability of intravenous ibandronate: 1- and 2-year data from DIVA. Endocr Practice 12 (2006) 44
89. Woo S.B., Hellstein J.W., and Kalmar J.R. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753-761
90. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
91. Melo M.D., and Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc 71 (2005) 111-113
92. Purcell P.M., and Boyd I.W. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 182 (2005) 417-418
93. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115-1117
94. Chesnut C.H., Ettinger M.P., Miller P.D., Baylink D.J., Emkey R., Harris S.T., et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 21 (2005) 391-401
95. Brown J.P., Kendler D.L., McClung M.R., Emkey R.D., Adachi J.D., Bolognese M.A., et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71 (2002) 103-111
96. Schnitzer T., Bone H.G., Crepaldi G., Adami S., McClung M., Kiel D., et al., Alendronate Once-Weekly Study Group. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) 12 (2000) 1-12
97. Cooper C., Emkey R.D., McDonald R.H., Hawker G., Bianchi G., Wilson K., et al. Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88 (2003) 4609-4615
98. Simon J.A., Lewiecki E.M., Smith M.E., Petruschke R.A., Wang L., and Palmisano J.J. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24 (2002) 1871-1876
99. Emkey R., Koltun W., Beusterien K., Seidman L., Kivitz A., Devas V., et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21 (2005) 1895-1903
100. Cramer J.A., Amonkar M.M., Hebborn A., and Suppapanya N. Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women?. [abstract M434]. J Bone Miner Res 19 (2004) S448
101. Cramer J.A., Amonkar M.M., Hebborn A., and Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21 (2005) 1453-1460